

SUPPLEMENTAL FINANCIAL INFORMATION



HISTORICAL GAAP P&L TREND - CONSOLIDATED (\$'000's)

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Revenue from products and services	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544	\$ 196,503	\$ 212,928	\$ 764,155	\$ 192,108
Cost of sales	41,126	42,979	47,990	55,205	187,300	53,184	56,443	59,203	63,437	232,267	55,632
Gross profit	97,351	102,594	102,729	121,588	424,262	115,996	129,101	137,300	149,491	531,888	136,476
Operating expenses:											
Research and development	18,012	19,105	20,357	23,244	80,718	16,582	18,276	18,679	22,281	76,268	17,560
Sales, general and administrative	113,727	112,731	109,200	114,541	450,199	127,017	118,507	124,303	128,699	498,526	137,057
Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525
Amortization of acquired intangibles	3,854	3,836	3,848	4,720	16,258	4,103	3,803	3,731	3,873	15,060	3,915
Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-
Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-
Gain on Settlement											
Total operating expenses	140,692	137,901	136,432	145,406	560,431	160,287	142,186	153,233	158,310	614,016	159,057
Operating Loss	(43,341)	(35,307)	(33,703)	(23,818)	(136,169)	(44,291)	(13,085)	(15,933)	(8,819)	(82,128)	(22,581)
Other expense, net:											
Cash interest expense, net	(4,283)	(4,754)	(5,417)	(5,967)	(20,421)	(5,356)	(5,289)	(5,312)	(5,184)	(21,141)	(4,953)
Noncash interest expense, net	(1,058)	(1,061)	(1,155)	(1,184)	(4,458)	(2,485)	(7,020)	(7,566)	(7,710)	(24,781)	(6,768)
Loss on debt extinguishment	-	-	-	-	-	(17,576)	-	-	-	(17,576)	-
Gain on derivative liability	-	-	-	-	-	17,400	(16,780)	-	-	620	-
Other (expense) income, net	118	156	623	(1,922)	(1,025)	337	993	307	(34)	1,603	446
Total other expense, net	(5,223)	(5,659)	(5,949)	(9,073)	(25,904)	(7,680)	(28,096)	(12,571)	(12,928)	(61,275)	(11,275)
Net loss before taxes	(48,564)	(40,966)	(39,652)	(32,891)	(162,073)	(51,971)	(41,181)	(28,504)	(21,747)	(143,403)	(33,856)
Income tax provision (benefit)	(69)	(286)	(36)	441	50	(64)	(37)	74	(18)	(45)	50
Net loss, GAAP	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)	\$ (28,578)	\$ (21,729)	\$ (143,358)	\$ (33,906)
Net loss per share, GAAP	\$ (0.34)	\$ (0.29)	\$ (0.28)	\$ (0.23)	\$ (1.13)	\$ (0.35)	\$ (0.27)	\$ (0.19)	\$ (0.14)	\$ (0.96)	\$ (0.22)
Weighted average shares outstanding, basic and diluted	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064	154,051

SUPPLEMENTAL FINANCIAL INFORMATION



NON-GAAP RECONCILIATION - CONSOLIDATED (\$000's)

NON-GAAP GROSS PROFIT & GROSS MARGIN	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Gross Profit, GAAP	\$ 97,351	\$ 102,594	\$ 102,729	\$ 121,588	\$ 424,262	\$ 115,996	\$ 129,101	\$ 137,300	\$ 149,491	\$ 531,888	\$ 136,476
+ Amortization of acquired intangible assets	307	307	308	(814)	108	50	64	65	66	245	66
+ Stock-based compensation	483	554	1,439	2,485	4,961	3,043	553	414	519	4,529	970
+ Purchase accounting adjustments on acquisitions	-	197	-	-	197	-	-	-	-	-	-
Non-GAAP Gross Profit	\$ 98,141	\$ 103,652	\$ 104,476	\$ 123,259	\$ 429,528	\$ 119,089	\$ 129,718	\$ 137,779	\$ 150,076	\$ 536,662	\$ 137,512
Gross Margin, GAAP	70.3%	70.5%	68.2%	68.8%	69.4%	68.6%	69.6%	69.9%	70.2%	69.6%	71.0%
+ Amortization of acquired intangible assets	0.2%	0.2%	0.2%	-0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
+ Stock-based compensation	0.3%	0.4%	1.0%	1.4%	0.8%	1.8%	0.3%	0.2%	0.2%	0.6%	0.5%
+ Purchase accounting adjustments on acquisitions	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Non-GAAP Gross Margin	70.9%	71.2%	69.3%	69.7%	70.2%	70.4%	69.9%	70.1%	70.5%	70.2%	71.6%

NON-GAAP OPERATING EXPENSES	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Research & Development, GAAP	\$ 18,012	\$ 19,105	\$ 20,357	\$ 23,244	\$ 80,718	\$ 16,582	\$ 18,276	\$ 18,679	\$ 22,281	\$ 76,268	\$ 17,560
- Stock-based compensation in R&D	4,315	5,614	7,207	9,894	27,030	3,644	4,159	3,307	8,421	19,531	4,001
Non-GAAP R&D	13,697	13,491	13,150	13,350	53,688	12,938	14,117	15,372	13,860	56,737	13,559
Sales General & Administrative, GAAP	113,727	112,731	109,200	114,541	450,199	127,017	118,507	124,303	128,699	498,526	137,057
- Stock-based compensation in SG&A	12,524	10,792	8,816	9,154	41,286	15,631	10,912	12,658	10,458	49,659	18,688
- Other non-recurring expenses	-	1,608	-	-	1,608	-	-	-	-	-	-
Non-GAAP SG&A	101,203	100,331	100,384	105,387	407,305	111,386	107,595	111,645	118,241	448,867	118,369
Other Operating Expense, GAAP	8,953	6,065	6,875	7,621	29,514	16,688	5,403	10,251	7,330	39,222	4,440
- Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525
- Amortization of acquired intangibles assets	3,854	3,836	3,848	4,720	16,258	4,103	3,803	3,731	3,873	15,060	3,915
- Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-
- Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-
Non-GAAP Other Operating Expense	-	-	-	-	-	-	-	-	-	-	-
Total Non-GAAP Operating Expenses	\$ 114,900	\$ 113,822	\$ 113,534	\$ 118,737	\$ 460,993	\$ 124,324	\$ 121,712	\$ 127,017	\$ 132,101	\$ 505,604	\$ 131,928
Non-GAAP Operating Expenses as a % of Revenue											
Research & development	9.9%	9.3%	8.7%	7.6%	8.8%	7.6%	7.6%	7.8%	6.5%	7.4%	7.1%
Sales, general & administrative	73.1%	68.9%	66.6%	59.6%	66.6%	65.8%	58.0%	56.8%	55.5%	58.7%	61.6%
Total Non-GAAP Operating Expenses as a % of Revenue	83.0%	78.2%	75.3%	67.2%	75.4%	73.5%	65.6%	64.6%	62.0%	66.2%	68.7%

SUPPLEMENTAL FINANCIAL INFORMATION



NON-GAAP RECONCILIATION - CONSOLIDATED (\$'000's)

ADJUSTED EBITDA	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Net loss, GAAP	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)	\$ (28,578)	\$ (21,729)	\$ (143,358)	\$ (33,906)
Cash interest expense, net	4,283	4,754	5,417	5,967	20,421	5,356	5,289	5,312	5,184	21,141	4,953
Noncash interest expense, net	1,058	1,061	1,155	1,184	4,458	2,485	7,020	7,566	7,710	24,781	6,768
Loss on debt extinguishment	-	-	-	-	-	17,576	-	-	-	17,576	-
Gain on derivative liability	-	-	-	-	-	(17,400)	16,780	-	-	(620)	-
Other (expense) income, net	(118)	(156)	(623)	1,922	1,025	(337)	(993)	(307)	34	(1,603)	(446)
Income tax provision (benefit)	(69)	(286)	(36)	441	50	(64)	(37)	74	(18)	(45)	50
Depreciation expense	13,724	15,735	16,491	16,102	62,052	15,754	15,012	14,889	14,695	60,350	14,629
Amortization expense	4,161	4,143	4,156	3,906	16,366	4,153	4,316	4,267	4,406	17,142	4,506
Total EBITDA	(25,456)	(15,429)	(13,056)	(3,810)	(57,751)	(24,384)	6,243	3,223	10,282	(4,636)	(3,446)
+ Stock-based compensation	17,322	16,960	17,462	21,533	73,277	22,318	15,624	16,379	19,398	73,719	23,659
+ Purchase accounting adjustments on acquisitions	-	197	-	-	197	-	-	-	-	-	-
+ Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525
+ Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-
+ Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-
+ Other non-recurring expenses	-	1,608	-	-	1,608	-	-	-	-	-	-
Total Adjusted EBITDA	\$ (3,035)	\$ 5,565	\$ 7,433	\$ 20,624	\$ 30,587	\$ 10,519	\$ 23,467	\$ 26,122	\$ 33,137	\$ 93,245	\$ 20,738
<i>Adjusted EBITDA as a % of Revenue</i>	<i>-2.2%</i>	<i>3.8%</i>	<i>4.9%</i>	<i>11.7%</i>	<i>5.0%</i>	<i>6.2%</i>	<i>12.6%</i>	<i>13.3%</i>	<i>15.6%</i>	<i>12.2%</i>	<i>10.8%</i>

NON-GAAP EARNINGS (LOSS) PER SHARE	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Net Loss, GAAP	\$ (48,495)	\$ (40,680)	\$ (39,616)	\$ (33,332)	\$ (162,123)	\$ (51,907)	\$ (41,144)	\$ (28,578)	\$ (21,729)	\$ (143,358)	\$ (33,906)
+ Stock-based compensation	17,322	16,960	17,462	21,533	73,277	22,318	15,624	16,379	19,398	73,719	23,659
+ Amortization of acquired intangible assets	4,161	4,143	4,156	3,906	16,366	4,153	3,867	3,796	3,939	15,305	3,981
+ Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-
+ Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-
+ Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525
+ Loss on Debt extinguishment	-	-	-	-	-	17,576	-	-	-	17,576	-
+ Gain on derivative liability	-	-	-	-	-	(17,400)	16,780	-	-	(620)	-
+ Noncash interest expense, net	1,058	1,061	1,155	1,184	4,458	2,485	7,020	7,566	7,710	24,781	6,768
+ Foreign exchange impact	(119)	(44)	(624)	1,592	805	(312)	(308)	(29)	(60)	(708)	(429)
+ Long-term income tax rate adjustment	5,448	4,606	3,800	21	13,875	2,811	(848)	(1,563)	(3,283)	(2,766)	(218)
Non-GAAP net income (loss)	\$ (15,526)	\$ (11,725)	\$ (10,640)	\$ (2,195)	\$ (40,086)	\$ (7,691)	\$ 2,591	\$ 4,091	\$ 9,432	\$ 8,091	\$ 380
Non-GAAP net income (loss) per share	\$ (0.11)	\$ (0.08)	\$ (0.07)	\$ (0.02)	\$ (0.28)	\$ (0.05)	\$ 0.02	\$ 0.03	\$ 0.06	\$ 0.05	\$ 0.00
Weighted avg shares outstanding, basic and diluted	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064	154,051

SUPPLEMENTAL FINANCIAL INFORMATION



NON-GAAP P&L TREND - CONSOLIDATED (\$'000's)

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Revenue from products and services	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544	\$ 196,503	\$ 212,928	\$ 764,155	\$ 192,108
Non-GAAP cost of sales	40,336	41,921	46,243	53,534	182,034	50,091	55,826	58,724	62,852	227,493	54,596
Non-GAAP gross profit	\$ 98,141	\$ 103,652	\$ 104,476	\$ 123,259	\$ 429,528	\$ 119,089	\$ 129,718	\$ 137,779	\$ 150,076	\$ 536,662	\$ 137,512
<i>Non-GAAP Gross Margin</i>	70.9%	71.2%	69.3%	69.7%	70.2%	70.4%	69.9%	70.1%	70.5%	70.2%	71.6%
Non-GAAP Operating expenses:											
Non-GAAP research & development	13,697	13,491	13,150	13,350	53,688	12,938	14,117	15,372	13,860	56,737	13,559
Non-GAAP sales, general & administrative	101,203	100,331	100,384	105,387	407,305	111,386	107,595	111,645	118,241	448,867	118,369
Total non-GAAP operating expenses	\$ 114,900	\$ 113,822	\$ 113,534	\$ 118,737	\$ 460,993	\$ 124,324	\$ 121,712	\$ 127,017	\$ 132,101	\$ 505,604	\$ 131,928
<i>Non-GAAP R&D as % of revenue</i>	9.9%	9.3%	8.7%	7.6%	8.8%	7.6%	7.6%	7.8%	6.5%	7.4%	7.1%
<i>Non-GAAP SG&A as % of revenue</i>	73.1%	68.9%	66.6%	59.6%	66.6%	65.8%	58.0%	56.8%	55.5%	58.7%	61.6%
<i>Total Non-GAAP OPEX as % of revenue</i>	83.0%	78.2%	75.3%	67.2%	75.4%	73.5%	65.6%	64.6%	62.0%	66.2%	68.7%
Non-GAAP operating income (loss)	(16,759)	(10,170)	(9,058)	4,522	(31,465)	(5,235)	8,006	10,762	17,975	31,058	5,584
<i>Op income (loss) as % of revenue</i>	-12.1%	-7.0%	-6.0%	2.6%	-5.1%	-3.1%	4.3%	5.5%	8.4%	4.1%	2.9%
<i>Cash interest expense</i>	4,283	4,754	5,417	5,967	20,421	5,356	5,289	5,312	5,184	21,141	4,953
<i>Other income</i>	1	1,693	1	330	2,025	(25)	(685)	(278)	94	(895)	(17)
<i>Long-term income tax rate adjustment</i>	(5,517)	(4,892)	(3,836)	420	(13,825)	(2,875)	811	1,637	3,265	2,721	268
Non-GAAP net income (loss)	(15,526)	(11,725)	(10,640)	(2,195)	(40,086)	(7,691)	2,591	4,091	9,432	8,091	380
Non-GAAP net income (loss) per share	\$ (0.11)	\$ (0.08)	\$ (0.07)	\$ (0.02)	\$ (0.28)	\$ (0.05)	\$ 0.02	\$ 0.03	\$ 0.06	\$ 0.05	\$ 0.00
Weighted avg shares outstanding, basic and diluted	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064	154,051
Non-GAAP operating income (loss)	(16,759)	(10,170)	(9,058)	4,522	(31,465)	(5,235)	8,006	10,762	17,975	31,058	5,584
Less: Other amortization expense	-	-	-	-	-	-	449	471	467	1,837.00	525
Less: Depreciation expense	13,724	15,735	16,491	16,102	62,052	15,754	15,012	14,889	14,695	60,350	14,629
Adjusted EBITDA	\$ (3,035)	\$ 5,565	\$ 7,433	\$ 20,624	\$ 30,587	\$ 10,519	\$ 23,467	\$ 26,122	\$ 33,137	\$ 93,245	\$ 20,738
<i>Adj EBITDA as % of revenue</i>	-2.2%	3.8%	4.9%	11.7%	5.0%	6.2%	12.6%	13.3%	15.6%	12.2%	10.8%
<i>Adj EBITDA drop through %</i>	14.5%	30.4%	24.2%	48.8%	30.7%	44.1%	44.8%	40.8%	34.6%	41.1%	44.6%

SUPPLEMENTAL FINANCIAL INFORMATION



REVENUE SUPPLEMENT

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Revenues:											
Products and services - Surgical	122,617	130,028	135,343	156,468	544,456	152,084	168,217	176,676	189,769	686,746	178,124
Products and services - EOS	15,860	15,545	15,376	20,325	67,106	17,096	17,327	19,827	23,159	77,409	13,984
Total revenue from products and services	\$ 138,477	\$ 145,573	\$ 150,719	\$ 176,793	\$ 611,562	\$ 169,180	\$ 185,544	\$ 196,503	\$ 212,928	\$ 764,155	\$ 192,108
Constant currency adjustments:											
Products and services - Surgical	67	18	(13)	(72)	-	180	80	75	93	428	(387)
Products and services - EOS	(88)	42	27	(146)	(165)	405	(167)	(435)	(589)	(786)	(727)
Revenue from products and services	(21)	60	14	(218)	(165)	585	(87)	(360)	(496)	(358)	(1,114)
TOTAL ADJUSTMENTS	(21)	60	14	(218)	(165)	585	(87)	(360)	(496)	(358)	(1,114)
Revenues at constant currency:											
Products and services - Surgical	122,684	130,046	135,330	156,396	544,456	152,264	168,297	176,751	189,862	687,174	177,737
Products and services - EOS	15,772	15,586	15,403	20,179	66,940	17,501	17,160	19,392	22,570	76,623	13,257
Total Revenue at Constant Currency	\$ 138,456	\$ 145,632	\$ 150,733	\$ 176,575	\$ 611,396	\$ 169,765	\$ 185,457	\$ 196,143	\$ 212,432	\$ 763,797	\$ 190,994

YOY GROWTH %	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126
Products and services - Surgical	30%	27%	30%	28%	29%	24%	29%	31%	21%	26%	17%
Products and services - EOS	5%	6%	6%	32%	13%	8%	11%	29%	14%	15%	-18%
Total revenue from products and services	27%	25%	27%	28%	27%	22%	27%	30%	20%	25%	14%
YOY growth % at constant currency:											
Products and services - Surgical	30%	27%	30%	28%	29%	24%	29%	31%	21%	26%	17%
Products and services - EOS	2%	7%	9%	34%	13%	11%	10%	26%	12%	14%	-24%
Total Revenue Growth % at Constant Currency	26%	25%	28%	28%	27%	23%	27%	30%	20%	25%	13%